Srdass Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.10 M
- Company Age 32 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
About Srdass Pharmaceuticals
Srdass Pharmaceuticals Pvt Ltd (SPPL) is a Private Limited Indian Non-Government Company incorporated in India on 24 June 1992 and has a history of 32 years and seven months. Its registered office is in Sangrur, Punjab, India.
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Rajiv Malhotra and Anshu serve as directors at the Company.
Company Details
-
Location
Sangrur, Punjab, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24232PB1992PTC012410
-
Company No.
012410
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
24 Jun 1992
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Chandigarh
Industry
What products or services does Srdass Pharmaceuticals Pvt Ltd offer?
Srdass Pharmaceuticals Pvt Ltd offers a wide range of products and services, including Ayurvedic,Herbal Products & Medicine, Ayurvedic Herbal Syrups & Tonics, Common Disease Medicines, Cough Syrup, Ayurvedic Medicine, Digestive System Drugs & Medicines, Digestive Drugs, Ayurvedic Pain Relief Oil, Herbal Piles Medicine, Cosmetics, Hair & Beauty Products.
Who are the key members and board of directors at Srdass Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajiv Malhotra
|
Director | 24-Jun-1992 | Current |
|
Anshu
|
Director | 30-Mar-2021 | Current |
Financial Performance of Srdass Pharmaceuticals.
Srdass Pharmaceuticals Pvt Ltd, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Srdass Pharmaceuticals?
In 2017, Srdass Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Srdass Pharmaceuticals?
Unlock and access historical data on people associated with Srdass Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Srdass Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Srdass Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
